Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Parallel-group Phase III Clinical Trial to Evaluate the Efficacy and Safety of YHP1701 Fixed Dose Combination in Patients With Dyslipidemia and Hypertension

Next Previous
Trial Profile

A Multi-center, Randomized, Double-blind, Parallel-group Phase III Clinical Trial to Evaluate the Efficacy and Safety of YHP1701 Fixed Dose Combination in Patients With Dyslipidemia and Hypertension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine/rosuvastatin (Primary) ; Amlodipine; Rosuvastatin
  • Indications Hyperlipidaemia; Hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Yuhan

Most Recent Events

  • 31 Jan 2020 Primary endpoint Change of mean seated Systolic Blood Pressure has been met as per results published in the Journal of Clinical Hypertension (Greenwich)
  • 31 Jan 2020 Primary endpoint, Percent change of LDL-Cholesterol, has been met as per results published in the Journal of Clinical Hypertension (Greenwich)
  • 31 Jan 2020 Results published in the Journal of Clinical Hypertension (Greenwich)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top